OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI

References

• Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25. doi:10.1007/s00261-017-1209-1
   PubMed Web of Science ®Google Scholar
• Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12(Suppl–1, M3):26–32. doi:10.2174/187435790181201002629541276
   PubMedGoogle Scholar
• Johnson PJ. How do mechanisms of hepatocarcinogenesis (HBV, HCV, and NASH) affect our understanding and approach to HCC?. Am Society Clin Oncol Educational Book. 2013;2013:132–136. doi:10.14694/EdBook_AM.2013.33.e132
   Google Scholar
• Narsinh KH, Cui J, Papadatos D, et al. Hepatocarcinogenesis and LI-RADS. Abdominal Radiol. 2018;43:1–11. doi:10.1007/s00261-017-1386-y
   PubMed Web of Science ®Google Scholar
• Wei WU, Min-Hua C, Maryellen S, et al. Contrast-enhanced ultrasound of hepatocarcinogenesis in liver cirrhosis. Chinese Medical Journal (English version) 2012;125(017):3104–3109.
   Google Scholar
• Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magnetic Resonance Med Ences. 2007;6(1):43–52. doi:10.2463/mrms.6.43
   PubMedGoogle Scholar
• Granito A, Galassi M, Piscaglia F, et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther. 2013;37(3):355–363. doi:10.1111/apt.1216623199022
   PubMed Web of Science ®Google Scholar
• Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metabol Disposition. 2010;38(7):1024–1028. doi:10.1124/dmd.110.032862
   PubMed Web of Science ®Google Scholar
• Verloh N, Haimerl M, Zeman F, et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol. 2014;24(5):1013–1019. doi:10.1007/s00330-014-3108-y24531844
   PubMed Web of Science ®Google Scholar
• Chung YE, Kim MJ, Kim YE, et al. Characterization of incidental liver lesions: comparison of multidetector CT versus Gd-EOB-DTPA-enhanced MR imaging. PLoS One. 2013;8.
   Web of Science ®Google Scholar
• Fujinaga Y, Ohya A, Matsushita T, et al. Effect of hepatobiliary uptake of Gd-EOB-DTPA on the hepatic venous phase of dynamic magnetic resonance imaging on a 3.0-T apparatus: comparison between Gd-EOB-DTPA and Gd-DTPA. Jpn J Radiol. 2011;29(10):695–700. doi:10.1007/s11604-011-0615-522009420
   PubMed Web of Science ®Google Scholar
• Furlan A, Marin D, Cabassa P, et al. Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol. 2012;81(9):2099–2105. doi:10.1016/j.ejrad.2011.07.01021906896
   PubMed Web of Science ®Google Scholar
• Avinash R, Kambadakon, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdominal Radiol. 2017.
   Web of Science ®Google Scholar
• Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic acid-enhanced MR imaging[J]. International Journal of Medical Radiology. 2012;261(3):834–844..
   Google Scholar
• Rhee H, Kim MJ, Park YN, et al. Gadoxetic acid -enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria. J Magn Reson Imaging. 2012;35:393–398. doi:10.1002/jmri.2282821990116
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, et al. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int. 2015;9(1):84–92. doi:10.1007/s12072-014-9553-525788383
   PubMed Web of Science ®Google Scholar
• Fu J, Zhao J, Zhang X, et al. Staging hepatocellular carcinoma with gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid -enhanced magnetic resonance imaging: a comparison with multi-detector row computed tomography. OMICS J Radiol. 2015;4. doi: 10.4172/2167-7964.1000e133
   PubMedGoogle Scholar
• Pastor CM, Mullhaupt B, Stieger B. The role of organic anion transporters in diagnosing liver diseases by magnetic resonance imaging. Drug Metab Dispos. 2014;42(4):675. doi:10.1124/dmd.113.05570724398460
   PubMed Web of Science ®Google Scholar
• Fukusato T, Soejima Y, Kondo F, et al. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res. 2015;45(10):E32–E42. doi:10.1111/hepr.1245325418671
   PubMed Web of Science ®Google Scholar
• Kitao A, Matsui O, Yoneda N, et al. The up take transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21(10):2056–2066. doi:10.1007/s00330-011-2165-821626360
   PubMed Web of Science ®Google Scholar
• Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features. Int J Med Radiol. 2010;256(3):817.
   Google Scholar
• Kitao A, Matsui O, Yoneda N, et al. Gadoxetic acid enhanced magnetic resonance imaging reflects co-activation of β-catenin and hepatocyte nuclear factor 4α in hepatocellular carcinoma. Hepatol Res. 2017;48(Suppl 19):205–216. doi:10.1111/hepr.1291128488786
   PubMed Web of Science ®Google Scholar
• Kitao A, Matsui O, Yoneda N, et al. Hepatocellular carcinoma with β-catenin mutation: imaging and pathologic characteristics. Radiology. 2015;275(3):708–717. doi:10.1148/radiol.1414131525668519
   PubMed Web of Science ®Google Scholar
• Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44(7):793–798.19404564
   PubMed Web of Science ®Google Scholar
• Beers BEV, Pastor CM, Hussain HK. Primovist, Eovist: what to expect?. J Hepatol. 2012;57:2.
   Web of Science ®Google Scholar
• Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44(7):793–798. doi:10.1007/s00535-009-0056-419404564
   PubMed Web of Science ®Google Scholar
• Doi N, Tomiyama Y, Kawase T, et al. Focal nodular hyperplasia-like nodule with reduced expression of organic anion transporter 1b3 in alcoholic liver cirrhosis. Internal Med. 2011;50(11):1193. doi:10.2169/internalmedicine.50.463721628934
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer. 2014;3(2):97–107. doi:10.1159/00034386524945000
   PubMed Web of Science ®Google Scholar
• Saitoh T, Sato S, Yazaki T, et al. Progression of hepatic hypovascular nodules with hypointensity in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI in hepatocellular carcinoma cases. Internal Med. 2018;57:2. doi:10.2169/internalmedicine.8801-16
   Web of Science ®Google Scholar
• Kitao A, Matsui O, Yoneda N, et al. The uptake transporter of Gd-EOB-DTPA (OATP8) expression decreases during hepatocarcinogenesis[C]//Radiological Society of North America 2010 Scientific Assembly and Annual Meeting. 2010.
   Google Scholar
• Kitao A, Matsui O, Yoneda N, et al. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic backgroundJ]. Eur Radiol. 2020;30:2. doi:10.1007/s00330-020-06687-y
   Web of Science ®Google Scholar
• Miura T, Ban D, Tanaka,等 S. Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signatureJ]. Am J Surg. 2015;210(3):561–569. doi:10.1016/j.amjsurg.2015.03.02726105803
   PubMed Web of Science ®Google Scholar
• Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocellular Carcinoma. 2018;5:61–73. doi:10.2147/JHC.S15670129984212
   PubMed Web of Science ®Google Scholar
• Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080–1087. doi:10.1016/j.jhep.2014.06.00824946283
   PubMed Web of Science ®Google Scholar
• Yoneda N, Matsui O, Kitao A, et al. Benign hepatocellular nodules: hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background. Radiographics Review Publication Radiological Society North America Inc. 2016;160037.
   Google Scholar
• Fujiwara H, Sekine S, Onaya H, et al. Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation. Jpn J Radiol. 2011;29(10):739–743. doi:10.1007/s11604-011-0624-422009428
   PubMed Web of Science ®Google Scholar